LTRN
LTRN
NASDAQ · Biotechnology

Lantern Pharma Inc

$1.12
-0.97 (-46.41%)
Financial Highlights (FY 2025)
Revenue
4.75M
Net Income
909.1K
Gross Margin
40.8%
Profit Margin
19.1%
Rev Growth
+21.8%
D/E Ratio
0.24
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 40.8% 40.8% 40.8%
Operating Margin 20.6% 22.4% 19.9%
Profit Margin 19.1% 18.5% 14.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 4.75M 4.21M 3.91M
Gross Profit 1.94M 1.72M 1.59M
Operating Income 979.5K 944.8K 775.4K
Net Income 909.1K 778.9K 578.2K
Gross Margin 40.8% 40.8% 40.8%
Operating Margin 20.6% 22.4% 19.9%
Profit Margin 19.1% 18.5% 14.8%
Rev Growth +21.8% +17.5% +9.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 4.41M 4.81M 3.82M
Total Equity 18.08M 16.17M 15.43M
D/E Ratio 0.24 0.30 0.25
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 1.38M 1.12M 1.11M
Free Cash Flow 932.9K 1.05M 869.6K